Attenuation of Intestinal Efflux Pump thru Polymers and Preservatives

Zakeri–Milani, Parvin; Baradaran, Behzad; Yousefi, Bahman; Valizadeh, Hassan; Mohammadzadeh, Ramin

doi:10.12991/jrp.2019.171

Cited by 4 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exosomes derived from CAFs enhance interferon‐related DNA damage resistance signature and increase the expression levels of Notch target genes, and therefore promote MDR in breast cancer cells . Exosomes derived from drug‐resistant breast cancer cells transmit MDR via delivery of P‐glycoprotein and miRNAs …”

Section: Resistance To Therapies Mediated By Breast Tumor Stromamentioning

confidence: 99%

Breast tumor stroma: A driving force in the development of resistance to therapies

Majidinia

Yousefi

2017

Chem Biol Drug Des

Self Cite

View full text Add to dashboard Cite

Breast cancer is the most common cancer and the second leading cause of cancer-related death in women worldwide. In spite of huge advancements in early detection and ever-increasing knowledge of breast cancer biology, approximately 30% of patients with early-stage breast cancer experience disease recurrence. Most patients are chemosensitive and cancer free immediately after the treatment. About 50% to 70% of breast cancer patients, however, will relapse within 1 year. Such a relapse is usually concomitant with adenocarcinoma cells acquiring a chemoresistant phenotype. Both de novo and acquired chemoresistance are poorly understood and present a major burden in the treatment of breast cancer. Although, previously, chemoresistance was largely linked to genetic alterations within the cancer cells, recent investigations are indicating that chemoresistance can also be associated with the tumor microenvironment. Nowadays, it is widely believed that tumor microenvironment is a key player in tumor progression and response to treatment. In this study, we will review the interactions of breast tumor cells with their microenvironment, present the latest research on the resistance mediated by the stromal component in breast cancer, and discuss the potential therapeutic strategies that can be exploited to treat breast cancers by targeting tumor microenvironment.

show abstract

Section: Resistance To Therapies Mediated By Breast Tumor Stromamentioning

confidence: 99%

Breast tumor stroma: A driving force in the development of resistance to therapies

Majidinia

Yousefi

2017

Chem Biol Drug Des

Self Cite

View full text Add to dashboard Cite

show abstract

“…Then they were ready to be used for the tests according to our previous study. 34 MiR-146a restoration Cells were seeded into a 6 well plate; 2×10 5 cells in each well, and incubated for 24 hours (h). After 24 h and as the first step, cells were transfected by miR-146a in a 6 well plate to set the optimum concentration.…”

Section: Breast Cancer Cell Culturementioning

confidence: 99%

MiR-146a Restoration Suppresses Triple-Negative Breast Cancer Cell Migration: A Bioinformatic and in Vitro Study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Purpose: Breast cancer is one of the most commonly diagnosed types of cancer worldwide. This cancer is treated with various methods like mastectomy, chemotherapy, hormone replacement therapy, and radiotherapy. Among them, targeted therapy, which specifically targets cancerous cells by using strategies like microRNA replacement therapy, is considered a new approach in treating breast cancer. Methods: Data analysis from TCGA datasets were used to confirm the decreased expression of miR-146a in breast cancer. MTT assay was used to evaluate the viability of MDA-MB-231 cells after miR-146a restoration. A wound-healing assay was used to observe migration in the MDA-MB-231 cell line and the effect of miR-146a on the migration. Finally, qRT-PCR was used as a method to determine the effect of miR-146a on the expression of CXCR4, β-catenin, MMP2, MMP9, and Vimentin genes are known to be involved in invasion and migration in MDA-MB-231 cell lines in breast cancer. Results: The bioinformatic study showed miR-146a expression decreased in breast tumors compared to adjusted normally. Our results indicated that miR-146a is not involved in apoptosis in the MDA-MB-231 cell line, while it is highly effective in migration inhibition. MMP9, MMP2, CXCR4, and Vimentin expressions were suppressed by miR-146a induction; however, it induced the expression of β-catenin which all result in inhibition of migration. Conclusion: Regulatory molecules, such as miR-146a, are effective in breast cancer targeted therapy. As cancer is a complicated disorder, therefore the combination of therapies, based on these targets might lead to novel therapeutic strategies.

show abstract

“…Reviewing the literature for formulations of traditional medicine and initial understanding of the COVID-19 disease, the authors formulated a novel herbal compound. Being a simple way for drug delivery and the most desired choice of the patients (14,15), this formula, which was composed of 18 herb components and is being patented in the Iranian Patent Office (IPO) with an application number of 139950140003008767, was prepared as compressed tablets. The tablets are composed mainly:…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Novel Herbal Tablets in COVID-19 Patients in Hospital Stay Days, ICU Admission and Mortality Rate Thereof: An Ppen-Label, Single-Blind Randomized Clinical Trial

Varshochi

Shahi

Rahimzadeh

et al. 2021

Jundishapur J Nat Pharm Prod

Self Cite

View full text Add to dashboard Cite

Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the super-spreading virus, has claimed hundreds of thousands of lives worldwide. Objectives: This study aimed to evaluate the effectiveness of the novel suggested herbal compound, formulated as compressed tablets, in reducing the length of hospital stay (LoS), intensive care unit (ICU) admission, and mortality in confirmed COVID-19 cases. Methods: Following an open-label, single-blind randomized clinical trial design, a total of 200 patients aged 18-65 admitted to Imam Reza hospital in Tabriz, northwest of Iran, were randomized to intervention and control groups in a 1:1 ratio, i.e., 100 subjects in each group. The former received standard treatment along with the compressed herbal tablets, and the latter only received the standard treatment. Adverse reactions incidence within 180 days after the beginning of the intervention was set as the primary safety endpoint. The most important and active ingredients of the tablets were Terminalia chebula, Glycyrrhiza glabra, Anacyclus pyrethrum, Senna alexandrina, Ferrula asafoetida, Pistacia lentiscus, Zizyphus jujuba, Crocus sativus, Echinacea angustifolia, and Hyssopus officinalis. This trial is registered at the Iranian Registry of Clinical Trials (code: IRCT20200522047545N1). Results: Those in the intervention arm had significantly lower rates of LoS (7.38 vs. 9.45, P = 0.030), ICU admission (6 out of 100 vs. 32 out of 100, P = 0.000), and mortality (1 vs. 19 out of 100, P = 0.000). Conclusions: Our observations suggest that adequate improvement is provided by the prepared herbal compound along with substantial savings in hospitalization hoteling costs. While further multi-center studies with a larger sample size are needed to extend our knowledge regarding the effect of this new option, these novel clinical data may well provide a new alternative for the management of COVID-19 disease.

show abstract

Attenuation of Intestinal Efflux Pump thru Polymers and Preservatives

Cited by 4 publications

References 36 publications

Breast tumor stroma: A driving force in the development of resistance to therapies

Breast tumor stroma: A driving force in the development of resistance to therapies

MiR-146a Restoration Suppresses Triple-Negative Breast Cancer Cell Migration: A Bioinformatic and in Vitro Study

Efficacy and Safety of Novel Herbal Tablets in COVID-19 Patients in Hospital Stay Days, ICU Admission and Mortality Rate Thereof: An Ppen-Label, Single-Blind Randomized Clinical Trial

Contact Info

Product

Resources

About